pmc logo image
Logo of jcmJ Clin Microbiol SubscriptionsJ Clin Microbiol Web Site

Formats:

J Clin Microbiol. 1997 January; 35(1): 111–116.
PMCID: PMC229521
Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.
R K Straubinger, B A Summers, Y F Chang, and M J Appel
James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA. rks4@cornell.edu
Abstract
In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. In contrast, B. burgdorferi was isolated from six of six untreated infected control dogs and joint lesions were found in four of these six dogs. Serum antibody levels to B. burgdorferi in all dogs declined after antibiotic treatment. Negative antibody levels were reached in four of six doxycycline- and four of six amoxicillin-treated dogs. However, in dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes. Antibody levels in untreated infected control dogs remained high.
Full Text
The Full Text of this article is available as a PDF (1.8M).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Alexander AD, Rule PL. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob Agents Chemother. 1986 Dec;30(6):835–839. [PubMed]
  • Alt DP, Bolin CA. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am J Vet Res. 1996 Jan;57(1):59–62. [PubMed]
  • Appel MJ, Allan S, Jacobson RH, Lauderdale TL, Chang YF, Shin SJ, Thomford JW, Todhunter RJ, Summers BA. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993 Mar;167(3):651–664. [PubMed]
  • Baradaran-Dilmaghani R, Stanek G. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection. 1996 Jan–Feb;24(1):60–63. [PubMed]
  • Barthold SW. Animal models for Lyme disease. Lab Invest. 1995 Feb;72(2):127–130. [PubMed]
  • Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. [PubMed]
  • Dattwyler RJ, Halperin JJ, Pass H, Luft BJ. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis. 1987 Jun;155(6):1322–1325. [PubMed]
  • Demaerschalck I, Ben Messaoud A, De Kesel M, Hoyois B, Lobet Y, Hoet P, Bigaignon G, Bollen A, Godfroid E. Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients. J Clin Microbiol. 1995 Mar;33(3):602–608. [PubMed]
  • Georgilis K, Peacocke M, Klempner MS. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J Infect Dis. 1992 Aug;166(2):440–444. [PubMed]
  • Goodman JL, Bradley JF, Ross AE, Goellner P, Lagus A, Vitale B, Berger BW, Luger S, Johnson RC. Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction. Am J Med. 1995 Jul;99(1):6–12. [PubMed]
  • Hassler D, Riedel K, Zorn J, Preac-Mursic V. Pulsed high-dose cefotaxime therapy in refractory Lyme borreliosis. Lancet. 1991 Jul 20;338(8760):193–193. [PubMed]
  • Häupl T, Hahn G, Rittig M, Krause A, Schoerner C, Schönherr U, Kalden JR, Burmester GR. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 1993 Nov;36(11):1621–1626. [PubMed]
  • Johnson RC, Kodner C, Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother. 1987 Feb;31(2):164–167. [PubMed]
  • Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2133–2136. [PubMed]
  • Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis. 1993 May;167(5):1074–1081. [PubMed]
  • Ma Y, Sturrock A, Weis JJ. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun. 1991 Feb;59(2):671–678. [PubMed]
  • Malawista SE, Barthold SW, Persing DH. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis. 1994 Nov;170(5):1312–1316. [PubMed]
  • Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, Steere AC. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396–403. [PubMed]
  • McClain JB, Ballou WR, Harrison SM, Steinweg DL. Doxycycline therapy for leptospirosis. Ann Intern Med. 1984 May;100(5):696–698. [PubMed]
  • McFadden P. Lyme disease research. Science. 1995 Dec 1;270(5241):1419–1419. [PubMed]
  • Moody KD, Adams RL, Barthold SW. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother. 1994 Jul;38(7):1567–1572. [PubMed]
  • Moter SE, Hofmann H, Wallich R, Simon MM, Kramer MD. Detection of Borrelia burgdorferi sensu lato in lesional skin of patients with erythema migrans and acrodermatitis chronica atrophicans by ospA-specific PCR. J Clin Microbiol. 1994 Dec;32(12):2980–2988. [PubMed]
  • Nadelman RB, Nowakowski J, Forseter G, Bittker S, Cooper D, Goldberg N, McKenna D, Wormser GP. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med. 1993 Jun;94(6):583–588. [PubMed]
  • Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):223–227. [PubMed]
  • Panconesi E, Zuccati G, Cantini A. Treatment of syphilis: a short critical review. Sex Transm Dis. 1981 Oct–Dec;8(4 Suppl):321–325. [PubMed]
  • Persing DH, Rutledge BJ, Rys PN, Podzorski DS, Mitchell PD, Reed KD, Liu B, Fikrig E, Malawista SE. Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis. 1994 Mar;169(3):668–672. [PubMed]
  • Preac Mursic V, Patsouris E, Wilske B, Reinhardt S, Gross B, Mehraein P. Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease. Infection. 1990 Nov–Dec;18(6):332–341. [PubMed]
  • Preac-Mursic V, Weber K, Pfister HW, Wilske B, Gross B, Baumann A, Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection. 1989 Nov–Dec;17(6):355–359. [PubMed]
  • Preac-Mursic V, Wilske B, Schierz G, Süss E, Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651–653. [PubMed]
  • Rahn DW. Antibiotic treatment of Lyme disease. Current recommendations by stage and extent of infection. Postgrad Med. 1992 May 15;91(7):57–64. [PubMed]
  • Rijpkema SG, Molkenboer MJ, Schouls LM, Jongejan F, Schellekens JF. Simultaneous detection and genotyping of three genomic groups of Borrelia burgdorferi sensu lato in Dutch Ixodes ricinus ticks by characterization of the amplified intergenic spacer region between 5S and 23S rRNA genes. J Clin Microbiol. 1995 Dec;33(12):3091–3095. [PubMed]
  • Sadziene A, Jonsson M, Bergström S, Bright RK, Kennedy RC, Barbour AG. A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect Immun. 1994 May;62(5):2037–2045. [PubMed]
  • Sambri V, Armati S, Cevenini R. Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement. FEMS Immunol Med Microbiol. 1993 Jun;7(1):67–71. [PubMed]
  • Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis. 1988 Oct;158(4):905–906. [PubMed]
  • Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, Zimmermann E, Goldberg NS, Bittker S, Campbell GL, Pavia CS. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol. 1992 Dec;30(12):3082–3088. [PubMed]
  • Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP, Duray PH, Larson MG, Wright EA, Ginsburg KS, Katz JN, Liang MH. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med. 1994 Oct 15;121(8):560–567. [PubMed]
  • Sigal LH. Current recommendations for the treatment of Lyme disease. Drugs. 1992 May;43(5):683–699. [PubMed]
  • Sigal LH. Persisting symptoms of Lyme disease--possible explanations and implications for treatment. J Rheumatol. 1994 Apr;21(4):593–595. [PubMed]
  • Steere AC. Lyme disease. N Engl J Med. 1989 Aug 31;321(9):586–596. [PubMed]
  • Straubinger RK, Chang YF, Jacobson RH, Appel MJ. Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J Clin Microbiol. 1995 Oct;33(10):2745–2751. [PubMed]
  • Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993 Mar–Apr;21(2):83–88. [PubMed]
  • Wahlberg P, Granlund H, Nyman D, Panelius J, Seppälä I. Treatment of late Lyme borreliosis. J Infect. 1994 Nov;29(3):255–261. [PubMed]
  • Watt G, Padre LP, Tuazon ML, Calubaquib C, Santiago E, Ranoa CP, Laughlin LW. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet. 1988 Feb 27;1(8583):433–435. [PubMed]